John Perfect, MD
Infectious Disease · Durham, NCNPI 1487717260
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,678 of the $5,828 with a category attached, or 80.3%. 3 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 50.2% of the total. Reporting peaked in 2019 at $2,928 and has fallen 60.7% since, to $1,150 in 2023.
Across 6 payments — averaging $971.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- Pfizer$2K
- Melinta Therapeutics, LLC$1K
Across 23 payments — averaging $7805.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$114K
- Pfizer$65K
- Mayne Pharma Commercial LLC$192
What the payments were for
- Consulting fees$1,15020%
- Speaking & faculty fees$4,67880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $2,928 |
| Pfizer | 2 | $1,750 |
| Melinta Therapeutics, LLC | 3 | $1,150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rezzayo$1,150
How this compares
$5,828 in reported general payments places this provider in the 80th percentile of 250 infectious disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Durham
- Cristina GasparettoDurham$613K
- Cameron WolfeDurham$112K
- Gordon CoreyDurham$46K
- Mitchell HorwitzDurham$45K
- Vance FowlerDurham$43K
- Sonali AdvaniDurham$37K
- Christopher WoodsDurham$16K
- Steve TaylorDurham$8K
- Barbara AlexanderDurham$6K
- Kara McGeeDurham$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.